Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 49

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 49
---
 we will not have any approved products and our pipeline will comprise solely of                                                                                                                                                 
 preclinical assets. The ADC Programs are early in development. Going forward, our business will depend on our ability to advance our current and future product candidates through preclinical studies and clinical trials and obtain regulatory approval 
 of our product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.                                                                                                                               |

| • |     | Through the License Agreement, we are transitioning to a new preclinical pipeline and pursuing different targets 
 and indications from those we have historically pursued, which has risks.                                        |

| • |     | The ADC Programs have never been tested in humans. They are comprised of antibodies that have never been tested             
 in humans and linker-payloads that are currently in clinical trials run by independent third parties for other indications. |

| • |     | Our product candidates are complex and can be difficult to manufacture. |

| • |     | We are currently dependent on single-source suppliers for our product candidates and their components, any issues 
 with such supplier, including increases in costs or expenses or delays in supply, could harm our business.        |

| • |     | We face substantial competition in oncology and in the ADC field. |

| • |     | We are dependent on third parties having accurately generated, collected, interpreted and reported data from 
 certain preclinical studies that were previously conducted for our product candidates.                       |

| • |     | We rely on third parties to conduct preclinical studies and clinical trials and for the manufacture, production,           
 storage and distribution of our products and product candidates and certain commercialization activities for our products. |

| • |     | We rely on in-license agreements for patent rights with respect to our product candidates and may in the future                                                                                                                                          
 acquire additional third-party intellectual property rights on which we may similarly rely. We face risks with respect to such reliance, including the risk that we could lose these rights that are important to our business if we fail to comply with 
 our obligations under these licenses.                                                                                                                                                                                                                    |

| • |     | Our business is subject to the risks associated with doing business in China. |

| • |     | U.S.-China trade relations may adversely impact our supply chain operations and business. |

Risks Related to Aadi For more information regarding risks related to Aadi’s historical business, as well as other risk factors applicable to Aadi and its industry, see “ Aadi Risk Factors” beginning on page 229.

- 33 -

RISK FACTORS